ACRV FY2025 EPS Estimate Lifted by Cantor Fitzgerald
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($1.95) per share for the year, up from their […]
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($1.95) per share for the year, up from their […]
